Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
November 06, 2023 09:15 ET
|
Cassava Sciences, Inc.
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end...
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
October 25, 2023 09:15 ET
|
Cassava Sciences, Inc.
Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD Conference in Boston, MA AUSTIN, Texas, Oct. ...
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
October 12, 2023 23:43 ET
|
Cassava Sciences, Inc.
CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.CUNY’s report finds that internal record-keeping...
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
October 05, 2023 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi...
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
October 02, 2023 09:00 ET
|
Cassava Sciences, Inc.
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately...
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
September 18, 2023 09:15 ET
|
Cassava Sciences, Inc.
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.The DSMB Recommended the Phase 3 Trials...
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
September 13, 2023 17:20 ET
|
Cassava Sciences, Inc.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
September 11, 2023 09:10 ET
|
Cassava Sciences, Inc.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
September 06, 2023 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it...
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
August 03, 2023 09:07 ET
|
Cassava Sciences, Inc.
Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023.Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an...